Abstract
Temozolomide (CCRG 81045: M&B 39831: NSC 362856) is an analogue of mitozolomide displaying similar broad spectrum activity in mouse tumours, but showing considerably less myelosuppression in the toxicology screen. Temozolomide was initially studied intravenously at doses between 50-200 mg m-2 and subsequently was given orally up to 1,200 mg m-2. A total of 51 patients were entered on the single dose schedule. Temozolomide exhibits linear pharmacokinetics with increasing dose. Myelotoxicity was dose limiting. Experimentally, temozolomide activity was schedule dependent and therefore oral administration was studied as a daily x 5 schedule between total doses of 750 and 1,200 mg m-2 in 42 patients. Myelosuppression was again dose limiting. The recommended dose for Phase II trials is 150 mg m-2 po for 5 days (total dose 750 mg m-2) for the first course, and if no major myelosuppression is detected on day 22 of the 4 week cycle, the subsequent courses can be given at 200 mg m-2 for 5 days (total dose 1 g m-2) on a 4 week cycle. Mild to moderate nausea and vomiting was dose related but readily controlled with antiemetics. Clinical activity was detected using the 5 day schedule in four (2CR, 2PR 17%) out of 23 patients with melanoma and in one patient with mycosis fungoides (CR lasting 7 months). Two patients with recurrent high grade gliomas have also had partial responses. Temozolomide is easy to use clinically and generally well tolerated. In the extended Phase I trial temozolomide only occasionally exhibited the unpredictable myelosuppression seen with mitozolomide.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Newlands, E., Blackledge, G., Slack, J. et al. Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65, 287–291 (1992). https://doi.org/10.1038/bjc.1992.57
Issue Date:
DOI: https://doi.org/10.1038/bjc.1992.57
This article is cited by
-
Netrin-4: Focus on Its Role in Axon Guidance, Tissue Stability, Angiogenesis and Tumors
Cellular and Molecular Neurobiology (2023)
-
Anti-tumor effects of vitamin D in glioblastoma: mechanism and therapeutic implications
Laboratory Investigation (2022)
-
Pharmacokinetics of metronomic temozolomide in cerebrospinal fluid of children with malignant central nervous system tumors
Cancer Chemotherapy and Pharmacology (2022)
-
Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma
Nature Biomedical Engineering (2021)
-
Characterization of Acidic Glycosphingolipid Changes in C6 Glioma Rats Treated With Temozolomide Using Ultra-High-Performance Liquid Chromatography Coupled With Quadrupole Time-of-Flight Mass Spectrometry
Journal of Analysis and Testing (2020)